Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence af Priestman, D, Welford, R, Platt, F, Muhlemann, A, Garzotti, M, Deymier, C, Ertel, E, Iglarz, M, Baldoni, D, Probst, M

Lucerastat, an iminosugar for substrate reduction therapy in Fabry Disease: Preclinical evidence af Welford, R, Mühleman, A, Priestman, D, Garzotti, M, Deymier, C, Ertel, E, Iglarz, M, Morand, O, Priestman, D, Platt, F, Probst, M

An international multicentre validation experiment for MOG antibodies af Reindl, M, Schanda, K, Woodhall, M, Tea, F, Ramanathan, S, Teegen, B, Sagen, J, Fryer, J, Mills, J, Mindorf, S, Ritter, N, Krummrei, U, Stoecker, W, Eggert, J, Rostasy, K, Berger, T, Irani, S, Dale, R, Probst, C, Brilot, F, Probst, M, Pittock, S, Waters, P

Epidemiology and clinical features of vivax malaria imported to Europe: Sentinel surveillance data from TropNetEurop af Malvy DJM, Kotlowski A, Iversen J, Knobloch J, Kapaun A, Kollaritsch H, Hatz C, Holthoff-Stich ML, Laferl H, Myrvang B, Schmid ML, Puente S, Hellgren U, Bisoffi Z, Lopez-Velez R, Matteelli A, McWhinney P, Björkman A, Clerinx J, Behrens RH, Gjørup I, Beran J, Schunk M, Zoller T, Probst M, Gascon J, Jelinek T, Mühlberger N, Kern P, Fry G, Siikamaki H, Schulze MH, Soula G, Paul M, Prat J Gómez i, Lehmann V, Bouchaud O, Cunha S da, Atouguia J, Boecken G

Få fuldtekst